Advertisement
Advertisement
U.S. Markets close in 4 hrs 32 mins
Advertisement
Advertisement
Advertisement
Advertisement

CTI BioPharma Corp. (CTIC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.59-0.13 (-2.36%)
As of 11:28AM EST. Market open.
Advertisement
Get access to 40+ years of historical data with Yahoo Finance Plus Essential.
Currency in USD

Valuation Measures4

Yahoo Finance Plus required to access annual data
Annual
Quarterly
Yahoo Finance Plus required to access monthly data
Monthly
Subscribe to Yahoo Finance Plus Essential to download historical data
 
As of Date: 1/30/2023
Current
Market Cap (intraday)
N/A
Enterprise Value
N/A
Trailing P/E
N/A
Forward P/E
N/A
PEG Ratio (5 yr expected)
N/A
Price/Sales (ttm)
N/A
Price/Book (mrq)
N/A
Enterprise Value/Revenue
N/A
Enterprise Value/EBITDA
N/A

Trading Information

Stock Price History

Beta (5Y Monthly) 0.91
52-Week Change 3N/A
S&P500 52-Week Change 3N/A
52 Week High 37.80
52 Week Low 31.82
50-Day Moving Average 35.71
200-Day Moving Average 35.65

Share Statistics

Avg Vol (3 month) 33.08M
Avg Vol (10 day) 32.71M
Shares Outstanding 596.69M
Implied Shares Outstanding 6N/A
Float 897.29M
% Held by Insiders 10.22%
% Held by Institutions 184.25%
Shares Short (Oct 13, 2022) 417.62M
Short Ratio (Oct 13, 2022) 43.96
Short % of Float (Oct 13, 2022) 416.74%
Short % of Shares Outstanding (Oct 13, 2022) 415.40%
Shares Short (prior month Sep 14, 2022) 417.06M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3Jan 02, 2017
Ex-Dividend Date 4N/A
Last Split Factor 21:10
Last Split Date 3Jan 02, 2017

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2021
Most Recent Quarter (mrq)Jun 29, 2022

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-695.70%

Management Effectiveness

Return on Assets (ttm)-59.98%
Return on Equity (ttm)-428.11%

Income Statement

Revenue (ttm)14.62M
Revenue Per Share (ttm)0.15
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -100.59M
Net Income Avi to Common (ttm)-120.8M
Diluted EPS (ttm)-0.74
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)95.87M
Total Cash Per Share (mrq)0.84
Total Debt (mrq)109.02M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)3.60
Book Value Per Share (mrq)0.53

Cash Flow Statement

Operating Cash Flow (ttm)-100.74M
Levered Free Cash Flow (ttm)-51.05M
Advertisement
Advertisement